- Home
- KALV vs NBTX Comparison
KALV vs NBTX Comparison
Compare KALV & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- NBTX
- Stock Information
- Founded
- KALV N/A
- NBTX 2003
- Country
- KALV United States
- NBTX France
- Employees
- KALV N/A
- NBTX N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- KALV Health Care
- NBTX Health Care
- Exchange
- KALV Nasdaq
- NBTX Nasdaq
- Market Cap
- KALV 796.4M
- NBTX 868.8M
- IPO Year
- KALV N/A
- NBTX 2020
- Fundamental
- Price
- KALV $10.95
- NBTX N/A
- Analyst Decision
- KALV Strong Buy
- NBTX Strong Buy
- Analyst Count
- KALV 8
- NBTX 1
- Target Price
- KALV $26.43
- NBTX $8.00
- AVG Volume (30 Days)
- KALV 1.5M
- NBTX 112.7K
- Earning Date
- KALV 09-11-2025
- NBTX 09-30-2025
- Dividend Yield
- KALV N/A
- NBTX N/A
- EPS Growth
- KALV N/A
- NBTX N/A
- EPS
- KALV N/A
- NBTX N/A
- Revenue
- KALV $1,426,000.00
- NBTX $11,930,711.00
- Revenue This Year
- KALV N/A
- NBTX N/A
- Revenue Next Year
- KALV $213.43
- NBTX $74.67
- P/E Ratio
- KALV N/A
- NBTX N/A
- Revenue Growth
- KALV N/A
- NBTX N/A
- 52 Week Low
- KALV $7.30
- NBTX $2.76
- 52 Week High
- KALV $17.28
- NBTX $22.51
- Technical
- Relative Strength Index (RSI)
- KALV 27.85
- NBTX 84.00
- Support Level
- KALV $11.93
- NBTX $19.11
- Resistance Level
- KALV $12.43
- NBTX $21.12
- Average True Range (ATR)
- KALV 0.60
- NBTX 1.61
- MACD
- KALV -0.22
- NBTX 0.79
- Stochastic Oscillator
- KALV 6.17
- NBTX 100.00
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.